Alaunos Therapeutics Inc (FRA:WEK)
€ 1.41 0 (0%) Market Cap: 326.90 Mil Enterprise Value: 325.31 Mil PE Ratio: 0 PB Ratio: 1.65 GF Score: 54/100

ZIOPHARM Oncology Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 01:20PM GMT
Release Date Price: €2.78 (+10.32%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Okay. Good morning, and thanks for tuning in to the JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst.

Our next presenting company this morning is Ziopharm Oncology. And here to tell us a little bit about the company. It's my pleasure to welcome Dr. Laurence Cooper, the CEO of the company.

Just to note, there will be a Q&A after the presentation. So feel free to submit a question, just click the Ask a Question icon.

With that, Lauren, thanks for sharing some of your time with us.

Laurence James Neil Cooper;CEO;Director

& -

Thank you, Eric, and everybody and for hosting such a great event in a virtual format. And I really appreciate everybody's efforts. So we're excited to be here to talk about our story and to engage with you all. Just as a reminder, on Slide 2 is the forward-looking statement. And -- so we'll go now to Slide 3. And I'd like to cover 4 topics today, which you can see on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot